AOD-9604 vs Tesamorelin
Research Verdict
Tesamorelin is the stronger research reference for the stated comparison criteria. Tesamorelin: FDA approved 2010 (Egrifta) for HIV-associated lipodystrophy, with Phase 3 RCTs showing significant visceral fat reduction (Falutz et al.
Quick Answers
Which is better, AOD-9604 or Tesamorelin?
Tesamorelin is the stronger research reference for the stated comparison criteria. Tesamorelin: FDA approved 2010 (Egrifta) for HIV-associated lipodystrophy, with Phase 3 RCTs showing significant visceral fat reduction (Falutz et al.
What is the key difference between AOD-9604 and Tesamorelin?
Tesamorelin is a GHRH analog stimulating endogenous GH release with proven visceral fat reduction; AOD-9604 is a GH fragment that was designed to reduce fat without GH elevation but failed to demonstrate clinical efficacy.
Evidence Comparison
Tesamorelin: FDA approved 2010 (Egrifta) for HIV-associated lipodystrophy, with Phase 3 RCTs showing significant visceral fat reduction (Falutz et al. NEJM 2007). AOD-9604: Phase 3 obesity trial failed primary endpoint. Tesamorelin has categorically stronger evidence with FDA approval and positive Phase 3 outcomes.
Evidence Context Favoring AOD-9604
GH-independent lipolysis research, with explicit acknowledgment of Phase 3 failure.
Evidence Context Favoring Tesamorelin
Any fat reduction or metabolic research requiring proven human efficacy - tesamorelin is FDA approved with positive Phase 3 data.
Side-by-Side Snapshot
| Evidence grade | AOD-9604: Level D Tesamorelin: Level A |
|---|---|
| Research status | AOD-9604: Preclinical Tesamorelin: FDA Approved |
| Primary category | AOD-9604: Weight Loss & Metabolic Tesamorelin: Growth Hormone |
| Cited studies | AOD-9604: 2 Tesamorelin: 3 |